Syngene Reports FY26 Revenue Rise And Board Changes

05 May 2026 CW Team

Net cash generated during the year was Rs. 5,210 mn after capital expenditure. Operating EBITDA for the year was Rs. 9,180 mn, down from Rs. 10,420 mn in the prior year, reflecting margin pressure. The results excluded a gratuity re-measurement credit of Rs. 200 mn and termination benefits of Rs. 250 mn recognised as exceptional. Management also disclosed an insurance settlement of Rs. 210 mn and an increase in gratuity liabilities of Rs. 380 mn.

The board confirmed several leadership changes. Kiran Mazumdar-Shaw became Executive Chairperson effective April 1, 2026 for a five-year term and Siddharth Mittal will take over as Managing Director and Chief Executive Officer effective July 1, 2026 for a five-year term. The board recommended Vijaya Chandru and Arun Chandavarkar as independent directors and reappointed Vinita Bali for one year. Maninder Kapoor Puri and Abhijit Zutshi join as Chief Human Resources Officer and Chief Commercial Officer respectively.

Syngene said it is expanding capabilities in antibody-drug conjugates and has commenced operations at an ADC discovery laboratory and a GMP bioconjugation suite to support discovery through manufacturing. The company completed 14 client and regulatory audits in the quarter and obtained GCP-NABL accreditation. An investor call was scheduled for 2 pm IST on April 30, 2026; replay is available until May 07, 2026 and a transcript will be posted within seven working days. The company serves global customers with over 8,300 employees and 3 mn sq. ft of specialised facilities.

Bengaluru, April 29, 2026: Syngene International Limited (Syngene) reported fourth quarter and full-year results for fiscal year 2026. Full-year revenue from operations rose three per cent to Rs. 37,390 mn and fourth quarter revenue rose two per cent year-on-year to Rs. 10,370 mn, up 13 per cent sequentially. Operating EBITDA margin for the quarter was 29 per cent and for the year 25 per cent. Profit after tax before exceptional items was Rs. 1,530 mn in the quarter and Rs. 3,800 mn for the year. Net cash generated during the year was Rs. 5,210 mn after capital expenditure. Operating EBITDA for the year was Rs. 9,180 mn, down from Rs. 10,420 mn in the prior year, reflecting margin pressure. The results excluded a gratuity re-measurement credit of Rs. 200 mn and termination benefits of Rs. 250 mn recognised as exceptional. Management also disclosed an insurance settlement of Rs. 210 mn and an increase in gratuity liabilities of Rs. 380 mn. The board confirmed several leadership changes. Kiran Mazumdar-Shaw became Executive Chairperson effective April 1, 2026 for a five-year term and Siddharth Mittal will take over as Managing Director and Chief Executive Officer effective July 1, 2026 for a five-year term. The board recommended Vijaya Chandru and Arun Chandavarkar as independent directors and reappointed Vinita Bali for one year. Maninder Kapoor Puri and Abhijit Zutshi join as Chief Human Resources Officer and Chief Commercial Officer respectively. Syngene said it is expanding capabilities in antibody-drug conjugates and has commenced operations at an ADC discovery laboratory and a GMP bioconjugation suite to support discovery through manufacturing. The company completed 14 client and regulatory audits in the quarter and obtained GCP-NABL accreditation. An investor call was scheduled for 2 pm IST on April 30, 2026; replay is available until May 07, 2026 and a transcript will be posted within seven working days. The company serves global customers with over 8,300 employees and 3 mn sq. ft of specialised facilities.

Real Estate

20 May 2026

WSB Invests in Omaxe for Tier II Expansion

WSB Partners, a real estate-focused investment firm, has invested Rs 750 million in Omaxe Group to support residential plotted developments in Ujjain and Indore.The investment marks WSB’s entry into Tier II markets and reflects growing institutional interest in emerging cities supported by infrastructure growth, improving affordability and rising housing demand.According to the companies, the funding will be deployed primarily as growth capital, with a portion allocated towards working capital and reserves. The investment has been undertaken alongside affiliates of WSB Partners and co-invest..

Infrastructure Transport

20 May 2026

RAHSTA Awards 2026 Opens for India’s Leading Road Developers

RAHSTA (Roads and Highways Sustainable Technologies & Advancement), Asia’s leading road infrastructure platform, has officially opened nominations for the RAHSTA Awards 2026 under the Road Developers category. The awards will honour companies and organisations that are shaping India’s highway infrastructure landscape through innovation, sustainability, quality execution and efficient asset management.Scheduled alongside RAHSTA 2026 on July 8–9, 2026 at the Jio World Convention Centre, Mumbai, the awards have emerged as one of the most respected recognitions for the roads and highways..

Infrastructure Transport

20 May 2026

Railways To Sell 10 per cent In PSUs To Raise Rs Two Point Six Two tn

The railway ministry has outlined a plan to sell up to 10 per cent stakes in several public sector undertakings as part of a broader asset monetisation drive. The move is designed to unlock value and generate funds for capital expenditure and network modernisation. The programme targets private participation through offer for sale and minority stake divestments across operating and finance entities. The initiative follows previous asset recycling efforts and seeks to capture market interest for strategic holdings. The target for the exercise is Rs two point six two trillion (tn) to be realised..